180 related articles for article (PubMed ID: 18167621)
21. [Cardiotoxicity of anthracyclines. Apropos of 12 pediatric cases].
Favrot MC; Pouyau G; Souillet G; Philip T; Bozzio A; Philippe N
Pediatrie; 1981 Sep; 36(6):437-50. PubMed ID: 6947199
[No Abstract] [Full Text] [Related]
22. Long-term cardiac safety of dose-dense anthracycline therapy cannot be predicted from early ejection fraction data.
Ewer MS; Ewer SM
J Clin Oncol; 2009 Dec; 27(36):6073-5. PubMed ID: 19901128
[No Abstract] [Full Text] [Related]
23. New iron chelators in anthracycline-induced cardiotoxicity.
Kaiserová H; Simunek T; Sterba M; den Hartog GJ; Schröterová L; Popelová O; Gersl V; Kvasnicková E; Bast A
Cardiovasc Toxicol; 2007; 7(2):145-50. PubMed ID: 17652820
[TBL] [Abstract][Full Text] [Related]
24. Other uses of dexrazoxane: Savene, the first proven antidote against anthracycline extravasation injuries.
Langer SW; Jensen PB; Sehested M
Cardiovasc Toxicol; 2007; 7(2):151-3. PubMed ID: 17652821
[TBL] [Abstract][Full Text] [Related]
25. Anthracycline cardiotoxicity in long-term survivors of childhood cancer.
Scully RE; Lipshultz SE
Cardiovasc Toxicol; 2007; 7(2):122-8. PubMed ID: 17652816
[TBL] [Abstract][Full Text] [Related]
26. [Dexrazoxane and cardiotoxicity in repeatedly treated patients].
Trnĕný M
Vnitr Lek; 2004 Jun; 50(6):417-8. PubMed ID: 15346632
[No Abstract] [Full Text] [Related]
27. Anthracycline cardiotoxicity.
Horan PG; McMullin MF; McKeown PP
Eur Heart J; 2006 May; 27(10):1137-8. PubMed ID: 16611672
[No Abstract] [Full Text] [Related]
28. [Cardiotoxicity in anthracycline chemotherapy: significance of infusion durations. Analysis of a Cochrane review].
Appel JM; Rybjerg M; Nielsen DL
Ugeskr Laeger; 2007 Sep; 169(37):3105-7. PubMed ID: 17877960
[No Abstract] [Full Text] [Related]
29. Protection by flavonoids against anthracycline cardiotoxicity: from chemistry to clinical trials.
Bast A; Haenen GR; Bruynzeel AM; Van der Vijgh WJ
Cardiovasc Toxicol; 2007; 7(2):154-9. PubMed ID: 17652822
[TBL] [Abstract][Full Text] [Related]
30. [Cardiac and vascular toxicity of chemotherapies].
Ederhy S; Ancedy Y; Champiat S; Lopez-Trabada-Ataz D; Dulery R; Cohen A
Rev Prat; 2018 Mar; 68(3):326-329. PubMed ID: 30869300
[TBL] [Abstract][Full Text] [Related]
31. Anthracyclines and cardiotoxicity.
Dodwell D
Clin Oncol (R Coll Radiol); 2000; 12(3):145. PubMed ID: 10942329
[No Abstract] [Full Text] [Related]
32. [Preventing the cardiotoxic effects of anthracyclines with Cardioxane].
Semiglazov VF
Vopr Onkol; 1997; 43(6):569-74. PubMed ID: 9479353
[No Abstract] [Full Text] [Related]
33. Cardiotoxicity of anthracyclines.
Green MD; Speyer JL; Muggia FM
Eur J Cancer Clin Oncol; 1984 Feb; 20(2):293-6. PubMed ID: 6584310
[No Abstract] [Full Text] [Related]
34. [Anthracycline cardiotoxicity: review].
Ribera JM; Montserrat E; Rozman C
Sangre (Barc); 1983; 28(1):54-68. PubMed ID: 6346540
[No Abstract] [Full Text] [Related]
35. Anthracycline cardiotoxicity: new insights.
Mushlin PS; Olson RD
Ration Drug Ther; 1988 Dec; 22(12):1-9. PubMed ID: 3256005
[No Abstract] [Full Text] [Related]
36. Prospective monitoring for anthracycline cardiotoxicity: an introduction.
McGuire WP
Cancer Treat Rep; 1978 Jun; 62(6):855. PubMed ID: 667858
[No Abstract] [Full Text] [Related]
37. The heart of the matter.
Portera CC; Swain SM
J Clin Oncol; 2007 Sep; 25(25):3794-6. PubMed ID: 17664459
[No Abstract] [Full Text] [Related]
38. Anthracycline cardiotoxicity: one size does not fit all!
Hershman DL; Neugut AI
J Natl Cancer Inst; 2008 Aug; 100(15):1046-7. PubMed ID: 18664649
[No Abstract] [Full Text] [Related]
39. Anthracyclines and cardiotoxicity.
Birtle AJ
Clin Oncol (R Coll Radiol); 2000; 12(3):146-52. PubMed ID: 10942330
[No Abstract] [Full Text] [Related]
40. Effectiveness of the combination therapy with lisinopril, ivabradine and multivitamin supplementation in anthracycline-induced severe cardiotoxicity.
de Gregorio C; Potenza G; Ferraro G
Int J Cardiol; 2014 Oct; 176(3):1374-6. PubMed ID: 25131909
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
